|
Mar 20
|
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
|
|
Mar 20
|
Novartis Reports Updated Positive Data From Phase III SMA Program
|
|
Mar 20
|
Novartis builds case for new SMA gene therapy
|
|
Mar 20
|
Novartis reports Phase III efficacy and safety outcomes of SMA treatment
|
|
Mar 20
|
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
|
|
Mar 19
|
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
|
|
Mar 19
|
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
|
|
Mar 17
|
Are You Looking for a High-Growth Dividend Stock?
|
|
Mar 17
|
Update: Market Chatter: Novartis Tracking US Reciprocal Tariff Policy 'Very Carefully'
|
|
Mar 17
|
Novartis is watching US reciprocal tariff policy 'very carefully', CEO says
|
|
Mar 14
|
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
|
|
Mar 3
|
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
|
|
Mar 1
|
3 Dividend Stocks That Are No-Brainer Buys Right Now
|
|
Feb 28
|
Q4 2024 PTC Therapeutics Inc Earnings Call
|
|
Feb 28
|
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
|
|
Feb 28
|
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
|
|
Feb 28
|
PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...
|
|
Feb 27
|
Q4 2024 Schrodinger Inc Earnings Call
|
|
Feb 27
|
Schrodinger Inc (SDGR) Q4 2024 Earnings Call Highlights: Strong Software Growth Amidst Revenue ...
|
|
Feb 26
|
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
|